According to the CDC, an estimated 1 in 13 children have food allergies. And at least 2 in 5 children, or 40 percent, have ...

Discover a study showing barzolvolimab rapidly improves chronic spontaneous urticaria symptoms, offering hope for patients ...

Chronic urticaria affects 17% of patients, with higher age, elevated BMI, and early prednisolone use as key determinants of prolonged disease duration. The study utilized data from the Julius General ...

First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic ...

In a safety-net hospital lacking allergy/immunology services, most patients with urticaria do not receive ...

Differentiated profile of ALY-301 designed to enable chronic dosing in mast cell dependent diseases while avoiding the safety limitations of conventional c-Kit inhibitors -- Multicenter Phase 1/1b ...

Dr S. Shahzad Mustafa looks ahead to ACAAI 2025, which will highlight advances in chronic urticaria treatment and ...

If over-the-counter antihistamines aren’t effective for you, your doctor may recommend H2 blockers, steroids, biologics, or ...

EXTON, PA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients ...

Novartis received approval from the Food and Drug Administration for Rhapsido (remibrutinib), an oral treatment for adults with chronic spontaneous urticaria. Rhapsido is the first Bruton’s tyrosine ...

Washington, DC, Oct. 01, 2025 (GLOBE NEWSWIRE) -- On this Urticaria Day (UDAY), the Asthma and Allergy Foundation of America (AAFA), We CU, and The Mast Cell Disease Society (TMS) aim to raise ...

Basel, September 30, 2025 – Novartis announced today that Rhapsido ® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic ...